INHIBITORS OF TRANSGLUTAMINASES
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use for the prophylaxis and treatment of diseases associated with transglutaminases.
3 Citations
15 Claims
-
1. A compound of the general formula (I):
wherein - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15)
-
2. The compound according to claim 1 having any one of the formulae (II-1)-(II-5):
-
3. The compound according to claim 1 having any one of the formulae (III-1) (III-5):
-
4. The compound according to claim 1 having any one of the formulae (VI-1)-(VI-5):
-
5. The Compound according to claim 1 having any one of the formulae (VII-3) (VII-4):
-
6. The compounds according to claim 1 of the formula (IX):
-
7. The compound according to claim 6 having the formula (XI-3):
-
8. The compound according to claim 1 having the formula (XIII);
-
9. The compound according to claim 8 having the formula (XIV-1)
-
10. The compound according to claim 1 selected from the group consisting of:
- (S)-methyl 2-((S)-1-((S)-2-((S)-2-acetamido-6-amino-5,6-dioxohexanamido)-3-methylbutanoyl)pyrrolidine-2-carboxamido)-4-methylpentanoate (E01),
(S)-methyl 2-((S)-1-((S)-2-((S)-6-amino-2-(benzyloxycarbonylamino)-5,6-dioxohexanamido)-3-methylbutanoyl)pyrrolidine-2-carboxamido)-4-methylpentanoate (E02), (S)-2-acetamido-N1-((S)-5-amino-1-((2S,3R)-1-((S)-1-amino-3-methyl-1-oxobutan-2-ylamino)-3-methyl-1-oxopentan-2-ylamino)-1,5-dioxopentan-2-yl)-5-oxohexanediamide (E03), (S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E04),(S)-2-(2-bromo-4-methylthiazole-5-carboxamido)-N1-(1-(2-(isopentylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-oxohexanediamide (E05), (S)-5-acetamido-6-(4-(2-chlorophenyl)piperazin-1-yl)-2,6-dioxohexanamide (E06), (S)-1-acetyl-N—
((S)-6-amino-1-(4-(3-methylpyridin-2-yl)piperazin-1-yl)-1,5,6-trioxohexan-2-yl)pyrrolidine-2-carboxamide (E07),(S)-1-((S)-2-((S)-1-((4R,7S,10S,13S,16S)-7-(4-amino-3,4-dioxobutyl)-10,13-dibutyl-4-(carboxymethyl)-18-methyl-2,5,8,11,14-pentaoxo-3,6,9,12,15-pentaazanonadecanecarbonyl)pyrrolidine-2-carboxamido)-3-(1H-indol-3-yl)propanoyl)pyrrolidine-2-carboxylic acid (E08), (S)—
N1-((S)-1-((R)-2-((S)-2-((S)-2-amino-1-cyclohexyl-2-oxoethylamino)-1-cyclohexyl-2-oxoethylcarbamoyl)piperidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-2-(6-hydroxy-5-nitronicotinamido)-5-oxohexanediamide (E09),3-((2S)-6-amino-1-((2S)-3-cyclopropyl-1-((1R,2S)-2-((2S)-1-((2S)-2-(1-(2,6-dimethylphenoxy)propan-2-ylcarbamoyl)-2-methylpyrrolidin-1-yl)-1-oxopentan-2-ylcarbamoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-3-yl)-1-oxopropan-2-ylamino)-1,5,6-trioxohexan-2-ylcarbamoyl)-5-nitrobenzoic acid (E10), (S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-oxo-2-(pyrazine-2-carboxamido)hexanediamide (E11),(S)-2-benzamido-N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-oxohexanediamide (E12), (S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-(2-methyl-5-nitrobenzamido)-5-oxohexanediamide (E13),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-(4-methylthiazole-5-carboxamido)-5-oxohexanediamide (E14),(S)-2-(5-(dimethylamino)naphthalene-1-sulfonamido)-N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-oxohexanediamide (E15), (S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E16),(S)—
N1-ethyl-N6-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-(1-methyl-1H-imidazole-5-carboxamido)-2-oxohexanediamide (E17),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxo-N6-pentylhexanediamide (E18),(S)—
N1-cyclopropyl-N6-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-(1-methyl-1H-imidazole-5-carboxamido)-2-oxohexanediamide (E19),(S)—
N1-benzyl-N6-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-(1-methyl-1H-imidazole-5-carboxamido)-2-oxohexanediamide (E20),(S)—
N1-tert-butyl-N6-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-(1-methyl-1H-imidazole-5-carboxamido)-2-oxohexanediamide (E21),(S)-2-((S)-1-acetylpyrrolidine-2-carboxamido)-N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-oxo-N6-pentylhexanediamide (E22), (S)-2-benzamido-N6-cyclopropyl-N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-oxohexanediamide (E23), (S)-methyl 2-((S)-1-((S)-2-((S)-2-benzamido-6-(cyclopropylamino)-5,6-dioxohexanamido)-3-methylbutanoyl)pyrrolidine-2-carboxamido)-4-methylpentanoate (E24), 4-((S)-1-((S)-1-((S)-2-((S)-2-((S)-2-amino-1-cyclohexyl-2-oxoethylamino)-1-cyclohexyl-2-oxoethylcarbamoyl)-4-oxopyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylamino)-6-(methylamino)-1,5,6-trioxohexan-2-ylcarbamoyl)nicotinic acid (E25), 4-((S)-1-((S)-1-((S)-2-((S)-2-((S)-2-amino-1-cyclohexyl-2-oxoethylamino)-1-cyclohexyl-2-oxoethylcarbamoyl)-4-oxopyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylamino)-6-(ethylamino)-1,5,6-trioxohexan-2-ylcarbamoyl)nicotinic acid (E26), 4-((S)-1-((S)-1-((S)-2-((S)-2-((S)-2-amino-1-cyclohexyl-2-oxoethylamino)-1-cyclohexyl-2-oxoethylcarbamoyl)-4-oxopyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylamino)-1,5,6-trioxo-6-(pentylamino)hexan-2-ylcarbamoyl)nicotinic acid (E27), 4-((S)-1-((S)-1-((S)-2-((S)-2-((S)-2-amino-1-cyclohexyl-2-oxoethylamino)-1-cyclo-hexyl-2-oxoethylcarbamoyl)-4-oxopyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl-amino)-6-(cyclopropylamino)-1,5,6-trioxohexan-2-ylcarbamoyl)nicotinic acid (E28), 4-((S)-1-((S)-1-((S)-2-((S)-2-((S)-2-amino-1-cyclohexyl-2-oxoethylamino)-1-cyclohexyl-2-oxoethylcarbamoyl)-4-oxopyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylamino)-6-(benzylamino)-1,5,6-trioxohexan-2-ylcarbamoyl)nicotinic acid (E29), 4-((S)-1-((S)-1-((S)-2-((S)-2-((S)-2-amino-1-cyclohexyl-2-oxoethylamino)-1-cyclohexyl-2-oxoethylcarbamoyl)-4-oxopyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylamino)-6-(tert-butylamino)-1,5,6-trioxohexan-2-ylcarbamoyl)nicotinic acid (E30), 4-((S)-6-amino-1-((S)-1-((S)-2-((S)-2-((S)-2-amino-1-cyclohexyl-2-oxoethylamino)-1-cyclohexyl-2-oxoethylcarbamoyl)-4-oxo pyrrolidi n-1-yl)-3,3-di methyl-1-oxo butan-2-ylamino)-1,5,6-trioxohexan-2-ylcarbamoyl)nicotinic acid (E31), (S)—
N1-((S)-1-((S)-2-((S)-2-((S)-2-amino-1-cyclohexyl-2-oxoethylamino)-1-cyclohexyl-2-oxoethylcarbamoyl)-4-oxopyrrolidin-1-yl)-3,3-di methyl-1-oxobutan-2-yl)-N6-cyclopropyl-2-(2-methylthiazole-4-carboxamido)-5-oxohexanediamide (E32),(S)—
N1-((S)-1-((2R,3S)-1-((S)-1-((S)-2-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-ylcarbamoyl)pyrrolidi n-1-yl)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxopentan-2-ylamino)-4-methyl-1-oxopentan-2-yl)-N6-cyclopropyl-2-(2-methylthiazole-4-carboxamido)-5-oxohexanediamide (E33),(S)-2-(2-acetamidoacetamido)-N1-((S)-1-((2S,3S)-1-((S)-1-((S)-2-((S)-1-amino-3-(1H-indol-3-yl)-1-oxo pro pan-2-ylcarbamoyl)pyrrolidi n-1-yl)-4-methyl-1-oxo pentan-2-ylamino)-3-methyl-1-oxopentan-2-ylamino)-1-oxohexan-2-yl)-N6-methyl-5-oxohexanediamide (E34), (S)-2-(2-((S)-1-acetylpyrrolidine-2-carboxamido)acetamido)-N1-((S)-1-((2S,3S)-1-((S)-1-((S)-2-((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-ylcarbamoyl)pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxopentan-2-ylamino)-1-oxohexan-2-yl)-N6-methyl-5-oxohexanediamide (E35), (S)-2-(2-((S)-1-(2-acetamidoacetyl)pyrrolidine-2-carboxamido)acetamido)-N1-((S)-1-((2S,3S)-1-((S)-1-((S)-2-((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-ylcarbamoyl)pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxopentan-2-ylamino)-1-oxohexan-2-yl)-N6-methyl-5-oxohexanediamide (E36), (S)-2-(2-((S)-1-(2-((S)-2-acetamido-4-methylpentanamido)acetyl)pyrrolidine-2-carboxamido)acetamido)-N1-((S)-1-((2S,3S)-1-((S)-1-((S)-2-((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-ylcarbamoyl)pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxopentan-2-ylamino)-1-oxohexan-2-yl)-N6-methyl-5-oxohexanediamide (E37), (S)-methyl 2-(6-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-5-(1-methyl-1H-imidazole-5-carboxamido)-2,6-dioxohexanamido)acetat (E38), (S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-(methoxymethyl)-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E39),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxo-N6-(thiazol-5-yl)hexanediamide (E40),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxo-N6-(tosylmethyl)hexanediamide (E41),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E42),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-5-methyl-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E43),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E44),(S)—
N1-(5-chloro-1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E45),(S)—
N1-(5-bromo-1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E46),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-5-(trifluoromethyl)-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E47),(S)-1-methyl-N-(6-(methylamino)-1,5,6-trioxo-1-(4-(phenylsulfonyl)piperazin-1-yl)hexan-2-yl)-1H-imidazole-5-carboxamide (E48), (S)—
N1-(1-benzylpiperidin-4-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E49),(S)—
N1-(1-(2-(diethylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E50),(S)—
N1-methyl-5-(1-methyl-1H-imidazole-5-carboxamido)-N6-(1-(2-(methylsulfonamido)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-oxohexanediamide (E51),(S)-ethyl 2-(3-(2-(1-methyl-1H-imidazole-5-carboxamido)-6-(methylamino)-5,6-dioxohexanamido)-2-oxopyridin-1(2H)-yl)acetate (E52), (S)-2-methoxyethyl 2-(3-(2-(1-methyl-1H-imidazole-5-carboxamido)-6-(methylamino)-5,6-dioxohexanamido)-2-oxopyridin-1(2H)-yl)acetate (E53), (S)—
N1-(1-(2-(methoxymethylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E54),(S)—
N1-(1-(2-((dimethylamino)methylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E55),(S)—
N1-(1-(2-(ethylsulfonamido)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-5-oxohexanediamide (E56),(S)-benzyl 1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-6-(methylamino)-1,5,6-trioxohexan-2-ylcarbamate (E57), (S)-tert-butyl 1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-6-(methylamino)-1,5,6-trioxohexan-2-ylcarbamate (E58), (S)-4-(1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-6-(methylamino)-1,5,6-trioxohexan-2-ylamino)-4-oxobutanoic acid (E59), (S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-5-oxo-2-((S)-4-oxopyrrolidine-2-carboxamido)hexanediamide (E60),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-(furan-3-carboxamido)-N6-methyl-5-oxohexanediamide (E61),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(oxazole-5-carboxamido)-5-oxohexanediamide (E62),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methylpiperidine-4-carboxamido)-5-oxohexanediamide (E63),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-5-oxo-2-(pyrimidine-5-carboxamido)hexanediamide (E64),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-5-oxo-2-(quinoxaline-2-carboxamido)hexanediamide (E65),(S)-2-(2,4-dimethylthiazole-5-sulfonamido)-N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-5-oxohexanediamide (E66), (S)-2-(6-chloroimidazo[2,1-b]thiazole-5-sulfonamido)-N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-5-oxohexanediamide (E67), (S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-2-(1-methyl-1H-imidazole-2-sulfonamido)-5-oxohexanediamide (E68),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-5-oxo-2-(3-phenylureido)hexanediamide (E69),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N6-methyl-5-oxo-2-(3-phenylthioureido)hexanediamide (E70),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N7-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-6-oxoheptanediamide (E71),(S)—
N1-methyl-6-(1-methyl-1H-imidazole-5-carboxamido)-N7-(4-(4-methylpiperazin-1-ylsulfonyl)phenyl)-2-oxoheptanediamide (E72),(S)—
N1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-N8-methyl-2-(1-methyl-1H-imidazole-5-carboxamido)-7-oxooctanediamide (E73),(S)—
N-(1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-1,5,6-trioxoheptan-2-yl)-1-methyl-1H-imidazole-5-carboxamide (E74),(S)—
N-(6-cyclopropyl-1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-1,5,6-trioxohexan-2-yl)-1-methyl-1H-imidazole-5-carboxamide (E75),(S)—
N-(1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-1,5,6-trioxo-6-phenylhexan-2-yl)-1-methyl-1H-imidazole-5-carboxamide (E76),(S)-methyl 6-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-5-(1-methyl-1H-imidazole-5-carboxamido)-2,6-dioxohexanoate (E77), (S)-2-methoxyethyl 6-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-5-(1-methyl-1H-imidazole-5-carboxamido)-2,6-dioxohexanoate (E78), (S)—
N1-(cyclopentylmethoxy)-N6-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)-5-(1-methyl-1H-imidazole-5-carboxamido)-2-oxohexanediamide (E79),(S)—
N-(1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-8-methyl-1,5,6-trioxononan-2-yl)-1-methyl-1H-imidazole-5-carboxamide (E80),(S)—
N-(1-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-ylamino)-6-(1-methyl-1H-imidazol-4-yl)-1,5,6-trioxohexan-2-yl)-1-methyl-1H-imidazole-5-carboxamide (E81),(2S)-N1-((S)-1-((S)-1-((S)-3-carbamoyl-3,4-dihydroisoquinolin-2(1H)-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-ylamino)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-2-(2-(5,5-dimethyl-2-oxotetrahydrofuran-3-yl)acetamido)-N6-methyl-5-oxohexanediamide (E82), (S)—
N1-(3-((S)-3-(biphenyl-4-yl)-1-((2S,4R)-2-carbamoyl-4-phenoxypyrrolidin-1-yl)-1-oxopropan-2-ylcarbamoyl)phenyl)-2-(2-(1,3-dimethyl-1H-pyrazol-5-yl)acetamido)-N6-methyl-5-oxohexanediamide (E83), andisopropyl (S)-1-((S)-1-(1-((2S,4R)-2-carbamoyl-4-hydroxypyrrolidin-1-yl)-2-methyl-1-oxopropan-2-ylamino)-5-guanidino-1-oxopentan-2-ylamino)-6-(methylamino)-1,5,6-trioxohexan-2-ylcarbamate (E84).
- (S)-methyl 2-((S)-1-((S)-2-((S)-2-acetamido-6-amino-5,6-dioxohexanamido)-3-methylbutanoyl)pyrrolidine-2-carboxamido)-4-methylpentanoate (E01),
-
12. A method for treatment or prophylaxis of atherosclerosis, coeliac disease, Duhring-Brocq-disease, gluten ataxia, tissue fibrosis, cystic fibrosis, kidney fibrosis and diabetic nephropathy, liver fibrosis, thrombosis, Huntington'"'"'s disease, Parkinson'"'"'s disease, Alzheimer'"'"'s disease, cataract, ichthyosis, acne, psoriasis, skin aging, and candidosis comprising administering the compound of claim 1 to a subject.
-
13. A method for producing a compound according to claim 1 comprising:
-
Step (0);
providing a protected amino acid having a chemical warhead;Step 1C;
deprotecting an amino protecting group PG2 and a carboxyl protecting group PG3;Step 1C′
;(a) performing coupling reaction of a resulting compound of Step 1C with a corresponding C-terminal amino acid building block H2ASCi-OPG4; (b) deprotecting the protecting group PG4; (c) repeating the steps (a) and (b) i times, wherein i is 1-8 Step 2C;
performing coupling reaction with a C-terminal building block EC-H;Step 3C;
deprotecting an amino protecting group PG1;Step 4C;
performing coupling reaction with a N-terminal building block EN-AG1;
to produce the compound of the formula (I).
-
-
14. The method according to claim 13 further comprising the Step 3C′
- between the step 3B and the step 4C;
Step 3C′
;(d) performing coupling reaction of a resulting compound of Step 3C with a corresponding N-terminal amino acid building block (PG5)HASNj-OH; (e) deprotecting the protecting group PG5; (f) repeating the steps (a) and (b) j times, wherein j is 1-4.
- between the step 3B and the step 4C;
-
15. A method for producing a compound according to claim 1 comprising:
-
Step (0);
providing a protected amino acid (1C′
) having a chemical warhead precursor (W′
);Step 1 D;
performing coupling reaction of the protected amino acid (1C′
) with a C-terminal peptide building block (C-P) or a C-terminal building block (EC-H) to obtain a compound 1D-1 or 1D-2;Step 2D;
deprotecting an amino protecting group PG1;
to obtain a compound 2D-1 or 2D-2;Step 3D;
performing coupling reaction of the compound 2D-1 or 2D-2 with a N-terminal peptide building block (N-P) or a N-terminal building block (EN-H);to obtain a compound 3D-1, 3D-2, 3D-3, or 3D-4; Step 4D;
converting the chemical warhead precursor (W′
) of the compound 3D-1, 3D-2, 3D-3, or 3D-4 to a chemical precursor (W)to produce a compound 4D-1, 4D-2, 4D-3, or 4D-4 as compound of the formula (I).
-
-
2. The compound according to claim 1 having any one of the formulae (II-1)-(II-5):
-
11. (canceled)
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeZedira GmbH
-
Original AssigneeZedira GmbH
-
InventorsHils, Martin, Pasternack, Ralf, Buchold, Christian
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current
-
CPC Class CodesA61K 38/00 Medicinal preparations cont...A61K 47/548 Phosphates or phosphonates,...A61P 1/00 Drugs for disorders of the ...A61P 7/02 Antithrombotic agents; Anti...C07D 213/75 Amino or imino radicals, ac...C07D 233/90 Carbon atoms having three b...C07D 295/185 from aliphatic carboxylic a...C07D 401/12 linked by a chain containin...C07D 401/14 containing three or more he...C07D 405/12 linked by a chain containin...C07D 413/12 linked by a chain containin...C07D 417/12 linked by a chain containin...C07D 417/14 containing three or more he...C07D 513/04 Ortho-condensed systemsC07K 5/0202 containing the structure -N...C07K 5/06165 and Pro-amino acid; Derivat...C07K 5/0819 with the first amino acid b...C07K 5/0821 with the first amino acid b...C07K 5/1013 the side chain containing O...C07K 5/1019 with the first amino acid b...C07K 5/1021 : with the first amino acid b...C07K 5/1024 : with the first amino acid b...